Physicochemical and Formulation Developability Assessment for Therapeutic Peptide Delivery—A Primer

AAPS Journal

Volumn 17, Issue 1, 2015, Pages 144-155

  Bak, Annette ^a   Leung, Dennis ^a   Barrett, Stephanie E ^a   Forster, Seth ^a   Minnihan, Ellen C ^a   Leithead, Andrew W ^a   Cunningham, James ^a,b   Toussaint, Nathalie ^a   Crocker, Louis S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALLERGAN INC   (United States)

Author keywords

developability; oral peptide delivery; parenteral peptide delivery; peptide therapeutics

Indexed keywords

CALCITONIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; OXYTOCIN; PEPTIDE; RECOMBINANT HUMAN INSULIN;

ARTICLE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PREFORMULATION; QUALITY CONTROL; RECTAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TRANSDERMAL DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; MEDICINAL CHEMISTRY; PATIENT PREFERENCE; PROCEDURES;

CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATIENT PREFERENCE; PEPTIDES;

EID: 84922076371     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9688-2     Document Type: Article

References (130)

1. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136–47.
2. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443–67.
3. Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol. 2009;27(11):628–35.
4. Sharma JPK, Bansal S, Banik A. Noninvasive routes of proteins and peptides drug delivery. Indian J Pharm Sci. 2011;73(4):367–75.
5. Transparency Market Research. Peptide therapeutics market—global industry analysis, size, share, growth, trends and forecast 2012–2018. Report; 2013. http://www.transparencymarketresearch.com/peptide-therapeutics-market.html.
6. Payne RW, Manning MC. Peptide formulation: challenges and strategies. Innov Pharm Technol. 2009;28:64–8.
7. Ohtake S, Kita Y, Payne R, Manning M, Arakawa T. Structural characteristics of short peptides in solution. Protein Pept Lett. 2013;20(12):1308–23.
8. Patel A, Cholkar K, Mitra AK. Recent developments in protein and peptide parenteral delivery approaches. Ther Deliv. 2014;5(3):337–65.
9. Brazeau GA, Cooper B, Svetic KA, Smith CL, Gupta P. Current perspectives on pain upon injection of drugs. J Pharm Sci. 1998;87(6):667–77.
10. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75.
11. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10(4):307–77.
12. Capasso S, Mazzarella L, Zagari A. Deamidation via cyclic imide of asparaginyl peptides: dependence on salts, buffers, and organic solvents. Pept Res. 1991;4(4):234–8.
13. Jang SW, Wo BH, Lee JT, Moon SC, Lee KC, DeLuca PP. Stability of octastatin, a somatostatin analog cyclic octapeptide, in aqueous solution. Pharm Dev Technol. 1997;2(4):409–14.
14. Houchin ML, Neuenswander SA, Topp EM. Effect of excipients on PLGA film degradation and the stability of an incorporated peptide. J Control Release. 2007;117(3):413–20.
15. Beals JM, DeFelippis MR, Kovach PM. Insulin. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology fundamentals and applications. 3rd ed. New York: Informa Healthcare USA, Inc; 2008. p. 265–80.
16. DeFelippis MR, Chance RE, Frank BH. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst. 2001;18(2):201–64.
17. Kelly RN, Lerke SA. Particle size measurement technique selection within method development in the pharmaceutical industry. Am Pharm Rev. 2005;8:72–81.
18. Xiao B, Tarricone C, Lin K, Kelly G, Justin N. Optimizing protein complexes for crystal growth. Cryst Growth Des. 2007;7:2213–8.
19. Wang YCJ, Hanson MA. Parenteral formulations of proteins and peptides: stability and stabilizers. PDA Technical Report Parenteral Drug Association. 1988.
20. Wei W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129–88.
21. Akers MJ, DeFelippis MR. Peptides and proteins as parenteral solutions. In: Hovgaard L, Frokjaer S, van de Weert M, editors. Pharmaceutical formulation development of peptides and proteins. 2nd ed. Boca Raton: Taylor & Francis Group, LLC; 2012. p. 150–92.
22. ICH. Stability Q1A-Q1F. [cited; Available from: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
23. Parkins DA, Lashmar UT. The formulation of biopharmaceutical products. Pharm Sci Technol Today. 2000;3(4):129–37.
24. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129–88.
25. Fransson JR, Hagman A. Oxidation of human insulin-like growth factor I in formulation studies, II. Effects of oxygen, visible light, and phosphate on methionine oxidation in aqueous solution and evaluation of possible mechanisms. Pharm Res. 1996;13(10):1476–81.
26. Li S, Schoneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48(5):490–500.
27. Li S, Schoneich C, Borchardt RT. Chemical pathways of peptide degradation. VIII. Oxidation of methionine in small model peptides by prooxidant/transition metal ion systems: influence of selective scavengers for reactive oxygen intermediates. Pharm Res. 1995;12(3):348–55.
28. Herman AC, Boone TC, Lu HS. Characterization, formulation, and stability of Neupogen(R) (Filgrastim), a recombinant human granulocyte-colony stimulating factor. In: Pearlman R, Want YJ, editors. Formulation, characterization, and stability of protein drugs: case histories. New York: Plenum Press; 1996. p. 324–5.
29. Knepp VM, Whatley JL, Muchnik A, Calderwood TS. Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor. PDA J Pharm Sci Technol. 1996;50(3):163–71.
30. Lam XM, Lai WG, Chan EK, Ling V, Hsu CC. Site-specific tryptophan oxidation induced by autocatalytic reaction of polysorbate 20 in protein formulation. Pharm Res. 2011;28(10):2543–55.
31. Li S, Schoneich C, Wilson GS, Borchardt RT. Chemical pathways of peptide degradation. V. Ascorbic acid promotes rather than inhibits the oxidation of methionine to methionine sulfoxide in small model peptides. Pharm Res. 1993;10(11):1572–9.
32. Akers MJ. Antioxidants in pharmaceutical products. J Parenter Sci Technol. 1992;36(5):222–8.
33. Harwood RJ, Portnoff JB, Sunbery EW. The processing of small volume parenterals and related sterile products. In: Avis KE, Lieberman HA, Lachaman L, editors. Pharmaceutical dosage forms: parenteral medications. New York: Marcel Dekker; 1993. p. 70–3.
34. Kerwin BA, Remmele Jr RL. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468–79.
35. Brange J, Langkjaer L. Insulin Structure and stability. In: Wang YJ, Pearlman R, editors. Stability and characterization of protein and peptide drugs: case histories. New York: Plenum Press; 1993. p. 315–50.
36. Brange J, Havelund S, Hougaard P. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res. 1992;9(6):727–34.
37. Mitraki A, King J. Protein folding intermediates and inclusion body formation. Nat Biotechnol. 1989;7:1491–5.
38. Shahrokh Z, Eberlein G, Wang YJ. Probing the conformation of protein (bFGF) precipitates by fluorescence spectroscopy. J Pharm Biomed Anal. 1994;12(8):1035–41.
39. Silvestri S, Lu MY, Johnson H. Kinetics and mechanisms of peptide aggregation. I: Aggregation of a cholecystokinin analogue. J Pharm Sci. 1993;82(7):689–93.
40. Rathore N, Rajan R. Current perspectives on stability of protein drug products during formulation, fill, and finish operations. Biotechnol Prog. 2008;24(3):504–14.
41. Maggio E. Use of excipients to control aggregation in peptide and protein formulations. J Excip Food Chem. 2010;1(2):40–9.
42. Allwood MC. The effectiveness of preservatives in insulin injections. Pharm J. 1982;229:340.
43. O’Neill JJ, Mead CA. The parabens: bacterial adaptation and preservative capacity. J Soc Cosmet Chem. 1982;33(2):75–84.
44. Denyer SP, Wallhaeusser K-H. Antimicrobial preservatives and their properties. In: Denyer SP, Baird RM, editors. Guide to microbiological control in pharmaceuticals. England: Ellis Horwood Limited; 1990. p. 251–73.
45. Pinholt C, Hartvig RA, Medicott NJ, Jorgensen L. The importance of interfaces in protein drug delivery—why is protein adsorption of interest in pharmaceutical formulations? Expert Opin Drug Deliv. 2011;8(7):949–64.
46. 6LHRH, a decapeptide, onto glass and other surfaces. Int J Pharm. 1983;16(2):181–90.
47. Dong DE, Andrade JD, Coleman DL. Adsorption of low density lipoproteins onto selected biomedical polymers. J Biomed Mater Res. 1987;21(6):683–700.
48. Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. Am J Hosp Pharm. 1977;34(6):583–8.
49. Johnston TP. Adsorption of recombinant human granulocyte colony stimulating factor (rhG-CSF) to polyvinyl chloride, polypropylene, and glass: effect of solvent additives. PDA J Pharm Sci Technol. 1996;50(4):238–45.
50. Schwarzenbach MS, Reimann P, Thommen V, Hegner M, Mumenthaler M, Schweb J, et al. Interferon alpha-2a interactions on glass vial surfaces measured by atomic force microscopy. PDA J Pharm Sci Technol. 2002;56(2):78–89.
51. Oshima G. Solid surface-catalysed inactivation of bovine alpha-chymotrypsin in dilute solution. Int J Biol Macromol. 1989;11(1):43–8.
52. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002;19(5):569–77.
53. Meckenzie IZ. Induction of labour at the start of the new millennium. Reproduction. 2006;131:989–98.
54. van Dongen PWJ, van Roosmalen J, de Boer CN, van Rooy RJ. Oxytocics for the prevention of postpartum haemorrhages, a review. Pharm Weekbl Sci. 1991;13:238–43.
55. Hogerzeil HV, Walker GJA, de Goeje MJ. Stability of injectable oxytocics in tropical climates. WHO Report. 1993;WHO/DAP/93.6.
56. Nachtmann F, Krummen K, Maxl F, Reimer E. Oxytocin. Analytical profiles of drug substances. Anal Prof Drug Subst. 1981;10:563–600.
57. Wisniewski K, Finnman J, Flipo M, Galyean R, Schteingart CD. On the mechanism of degradation of oxytocin and its analogues in aqueous solution. Biopolymers. 2013;100(4):408–21.
58. Hawe A, Poole R, Romeijn S, Kasper P, van der Heijden R, Jiskoot W. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res. 2009;26(7):1679–88.
59. Avanti C, Amorij J-P, Setyaningsih D, Hawe A, Jiskoot W, Visser J, et al. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. AAPS J. 2011;13(2):284–90.
60. Avanti C, Permentier HP, van Dam A, Poole R, Jiskoot W, Frijlink HW, et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm. 2012;9(3):554–62.
61. Avanti C, Oktaviani NA, Hinrichs WLJ, Frijlink HW, Mulder FAA. Aspartate buffer and divalent metal ions affect oxytocin in aqueous solution and protect it from degradation. Int J Pharm. 2013;444(1–2):139–45.
62. Malm M, Nilsson A, Siekmann B, Wisniewski K, inventors; Ferring B.V., assignee. Pharmaceutical composition. Patent WO 2012042371 A2. 2012 April 5.
63. Beauchesne PR, Chung NSC, Warsan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33(3):211–20.
64. Czogalla A. Oral cyclosporine A—the current picture of its liposomal and other delivery systems. Cell Mol Biol Lett. 2008;14(1):139–52.
65. Ritschel WA. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin Transpl. 1996;10(4):364–73.
66. Bak A, McGregor C, Templeton A. Scientific risk assessment strategies for managing the transition from discovery to development. AAPS Newsmag. 2010.
67. Bak A. Physicochemical and formulation risk assessment for subcutaneous peptide delivery. AAPS Annual Meeting and Exposition. San Antonio; 2013.
68. Christensen S, Horn Moeller E, Bonde C, Lilleoere AM. Preliminary studies of the physical stability of a glucagon-like peptide-1 derivate in the presence of metal ions. Eur J Pharm Biopharm. 2007;66(3):366–71.
69. Graf A, Jack KS, Whittaker AK, Hook SM, Rades T. Protein delivery using nanoparticles based on microemulsions with different structure-types. Eur J Pharm Sci. 2008;33(4–5):434–44.
70. Wolk C, Drescher S, Meister A, Blume A, Langner A, Dobner B. General synthesis and physicochemical characterisation of a series of peptide-mimic lysine-based amino-functionalised lipids. Chem Eur J. 2013;19(38):12824–38.
71. Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules. 2014;15(1):350–60.
72. Carafa M, Marianecci C, Annibaldi V, Di Stefano A, Sozio P. Novel O-palmitoylscleroglucan-coated liposomes as drug carriers. Int J Pharm. 2006;325(1–2):155–62.
73. Chen C, Fan T, Jin Y, Zhou Z, Yang Y, Zhu X. Orally delivered salmon calcitonin-loaded solid lipid nanoparticles. Nanomedicine. 2013;8(7):1085–100.
74. Paterson AD, Conradi RA, Hilgers AR, Vidmar TJ, Burton PS. A non-aqueous partitioning system for predicting the oral absorption potential of peptides. Quant Struct-Act Rel. 1994;13(4):4–10.
75. Sandhya KW, Devi GS, Mathew ST. Liposomal formulations of serratiopeptidase: in vitro studies using PAMPA and Caco-2 models. Mol Pharm. 2008;5(1):92–7.
76. Gu C-H, Li L, Levons J, Lentz K, Gandhi RB, Raghavan K, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24(6):1118–30.
77. Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharm. 2011;51(4):460–71.
78. Marais E, Hamman J, du Plessis L, Lemmer R, Steenekamp J. Eudragit® L100/N-trimethylchitosan chloride microspheres for oral insulin delivery. Molecules (Basel, Switzerland). 2013;18(6):6734–47.
79. Cui X, Cao D, Zhang X, Zheng A. A study of the chemical and biological stability of vasoactive intestinal peptide. Drug Dev Ind Pharm. 2013;39(12):1907–10.
80. Mehta NM. Oral delivery and recombinant production of peptide hormones part I. Biopharm Int. 2004;17(6):38–43.
81. Langguth P, Bohner V, Heizmann J, Merkle HP, Wolffram S. The challenge of proteolytic enzymes in intestinal peptide delivery. J Control Release. 1997;46(1–2):39–57.
82. Fuhrmann G, Leroux J-C. In vitro evaluation of the stability of proline-specific endopeptidases. J Control Release. 2010;148(1):e37–9.
83. Kahns AH, Bundgaard H. Facile α-chymotrypsin-catalyzed degradation of the HIV inhibitor [d-Ala1]-peptide T amide. Int J Pharm. 1991;77(1):65–70.
84. Haeberlin B, Gengenbacher T, Meinzer A, Fricker G. Cyclodextrins—useful excipients for oral peptide administration? Int J Pharm. 1996;137(1):103–10.
85. Allémann E, Leroux J-C, Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev. 1998;34(2–3):171–89.
86. Christophersen PC, Zhang L, Yang M, Nielsen HM, Mullertz A. Solid lipid particles for oral delivery of peptide and protein drugs I—elucidating the release mechanism of lysozyme during lipolysis. Eur J Pharm Biopharm. 2013;85(3):473–80.
87. Cilek A, Celebi N, Tırnaksız F. Lecithin-based microemulsion of a peptide for oral administration: preparation, characterization, and physical stability of the formulation. Drug Deliv. 2006;13(1):19–24.
88. Kirby CJ. Oil-based formulations for oral delivery of therapeutic peptides. J Liposome Res. 2000;10(4):391–407.
89. Banerjee A, Onyuksel H. Peptide delivery using phospholipid micelles. Wiley Interdisc Rev Nanomed Nanobiotechnol. 2012;4(5):562–74.
90. Kumar TRS, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol. 2006;7(4):261–76.
91. Kavimandan NJ, Losi E, Wilson JJ, Brodbelt J. Synthesis and characterization of insulin–transferrin conjugates. Bioconjug Chem. 2006;17(6):1376–84.
92. Xia CQ, Wang J, Shen W-C. Hypoglycemic effect of insulin–transferrin conjugate in streptozotocin-induced diabetic rats. J Pharm Exp Ther. 2000;295(2):594–600.
93. Youn YS, Chae SY, Lee S, Kwon MJ, Shin H. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. Eur J Pharm Biopharm. 2008;68(3):667–75.
94. Mizuma T, Koyanagi A, Awazu S. Intestinal transport and metabolism of glucose-conjugated kyotorphin and cyclic kyotorphin: metabolic degradation is crucial to intestinal absorption of peptide drugs. Biochim Biophys Acta. 2000;475(1):90–8.
95. des Rieux A, Fievez V, Momtaz M, Detrembleur C, Alonso-Sande M, Van Gelder J, et al. Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J Control Release. 2007;118(3):294–302.
96. Kristensen M, Foged C, Berthelsen J, Nielsen HM. Peptide-enhanced oral delivery of therapeutic peptides and proteins. J Drug Del Sci Technol. 2013;23(4):365–73.
97. Maher S, Brayden DJ, Feighery L, McClean S. Cracking the junction: update on the progress of gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs. Crit Rev Ther Drug Carrier Syst. 2008;25(2):117–68.
98. Maher S, Brayden DJ. Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov Today Technol. 2012;9(2):e113–9.
99. Harris D, Robinson JR. Bioadhesive polymers in peptide drug delivery. Biomaterials. 1990;11(9):652–8.
100. Lehr CM, Bouwstra JA, Kok W, De Boer AG. Effects of the mucoadhesive polymer polycarbophil on the intestinal absorption of a peptide drug in the rat. J Pharm Pharmacol. 1992;44(5):402–7.
101. Balamurugan M. Chitosan: a perfect polymer used in fabricating gene delivery and novel drug delivery system. Int J Pharm Pharm Sci. 2012;4(3):54–6.
102. Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schatzlein AG. Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol Pharm. 2012;9(6):1764–74.
103. 5-enkephalin, to the brain. Mol Pharm. 2012;9(6):1665–80.
104. Bernkop-Schnuerch A, Pinter Y, Guggi D, Kahlbacher H. The use of thiolated polymers as carrier matrix in oral peptide delivery—proof of concept. J Control Release. 2005;106(1–2):26–33.
105. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci. 2010;99(1):1–20.
106. Shah AR, Agarwal K, Baker ES, Singhal M. Machine learning based prediction for peptide drift times in ion mobility. Bioinformatics. 1991;26(13):1601–7.
107. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2005;2(3):533–48.
108. Singh N, Kalluri H, Herwadkar A, Badkar A, Banga AK. Transcending the skin barrier to delivery peptides and proteins using active technologies. Crit Rev Ther Drug Carrier Syst. 2012;29(4):265–98.
109. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.
110. Wu F, Yang S, Yuan W, Jin T. Challenges and strategies in developing microneedle patches for transdermal delivery of protein and peptide therapeutics. Curr Pharm Biotechnol. 2012;13:1292–8.
111. Grant M, Leone-Bay A. Peptide therapeutics: it’s all in the delivery. Ther Deliv. 2012;3(8):981–96.
112. Pharma Z. Zosano Pharma enters into a license agreement with Novo Nordisk to deliver semaglutide using Zosano’s microneedle patch system. 2013 [cited; Available from: http://www.zosanopharma.com/index.php/20130514224/News/Press-Releases/Zosano-Pharma-Enters-into-a-License-Agreement-with-Novo-Nordisk-to-Deliver-Semaglutide-Using-Zosano.html.
113. Kanikkannan N. Iontophoresis-based transdermal delivery systems. BioDrugs. 2002;16(5):339–47.
114. Sen A, Daly ME, Hui SW. Transdermal insulin delivery using lipid enhanced electroporation. Biochim Biophys Acta - Biomembr. 2002;1564(1):5–8.
115. Boucaud A, Garrigue MA, Machet L, Vaillant L, Patat F. Effect of sonication parameters on transdermal delivery of insulin to hairless rats. J Control Release. 2002;81(1–2):113–9.
116. Schramm J, Mitragotri S. Transdermal drug delivery by jet injectors: energetics of jet formation and penetration. Pharm Res. 2002;19(11):1673–9.
117. Merkle HP, Wolany G. Buccal delivery for peptide drugs. J Control Release. 1992;21(1–3):155–64.
118. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm. 2001;51(2):93–109.
119. Soares S, Costa A, Sarmento B. Novel non-invasive methods of insulin delivery. Expert Opin Drug Deliv. 2012;9(12):1539–58.
120. Niu C-H, Chiu Y-Y. FDA perspective on peptide formulation and stability issues. J Pharm Sci. 1998;87(11):1331–4.
121. Uchenna Agu R, Ikechukwu Ugwoke M, Armand M, Kinget R, Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2(4):198–209.
122. Kaspar A, Reichert J. Future directions for peptide therapeutics development. Drug Discov Today. 2013;18(17–18):807–17.
123. Dombu CY, Betbeder D. Airway delivery of peptides and proteins using nanoparticles. Biomaterials. 2013;34(2):516–25.
124. Qian F, Mathias N, Moench P, Chi C, Desikan S. Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. Int J Pharm. 2009;366(1–2):218–20.
125. Hamilton HW, Steinbaugh BA, Stewart BH, Chan H, Schmid HL, Schroeder R, et al. Evaluation of physicochemical parameters important to the oral bioavailability of peptide-like compounds: implications for the synthesis of renin inhibitors. J Med Chem. 1995;38(9):1446–55.
126. Nofsinger R, Borchardt R. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P450 enzymes in the intestinal mucosa. J Pharm Sci. 2012;101(9):3500–10.
127. Onoue S, Misaka S, Ohmori Y, Sato H, Mizumoto T, Hirose M, et al. Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability. Eur J Pharm Biopharm. 2009;73(1):95–101.
128. Rotivala R, Bernarda M, Henrieta T, Fourgeauda M, Fabreguettesa JR, Surgeta E, et al. Comprehensive determination of the cyclic FEE peptide chemical stability in solution. J Pharm Biomed Anal. 2014;89:50–5.
129. Lai MC, Hageman MJ, Schowen RL, Borchardt RT, Laird BB, Topp EM. Chemical stability of peptides in polymers. 2. Discriminating between solvent and plasticizing effects of water on peptide deamidation in poly(vinylpyrrolidone). J Pharm Sci. 1999;88(10):1081–9.
130. Guo L, Ma E, Zhao H, Long Y, Zheng C. Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. Int J Pharm. 2011;420(1):172–9.